27. Aklief

Galderma Logo

Active ingredient: trifarotene
Disease: acne
Peak sales estimate: n/a
Approved: Oct. 4, 2019
Company: Galderma

The scoop: Aklief isn’t just a different formulation of an existing retinoid, it’s an entirely new retinoid molecule, the first to receive FDA approval for the treatment of acne in over 20 years. Two identical phase 3 studies on a total of 2,420 patients showed that the topical drug could reduce inflammatory lesions on the face in two weeks and on the back, shoulders and chest after four weeks, both significantly superior over the vehicle. The drug is also expected to be safer than older retinoids with fewer side effects such as application site irritation. The nod was the first one for Galderma as a standalone company after Nestlé exited skin health and spun it off to a consortium led by EQT Partners and the Abu Dhabi Investment Authority’s subsidiary Luxinva for CHF 10.2 billion. The company is now run by ex-Shire CEO Flemming Ornskov. — Angus Liu

27. Aklief

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.